0001209191-20-063391.txt : 20201215 0001209191-20-063391.hdr.sgml : 20201215 20201215120933 ACCESSION NUMBER: 0001209191-20-063391 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201211 FILED AS OF DATE: 20201215 DATE AS OF CHANGE: 20201215 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Smith David V CENTRAL INDEX KEY: 0001229447 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36070 FILM NUMBER: 201388826 MAIL ADDRESS: STREET 1: 6035 STONERIDGE DRIVE CITY: PLEASANTON STATE: CA ZIP: 94588 FORMER NAME: FORMER CONFORMED NAME: SMITH DAVID V DATE OF NAME CHANGE: 20030429 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: FIVE PRIME THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001175505 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 260038620 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 111 OYSTER POINT BOULEVARD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 415-365-5600 MAIL ADDRESS: STREET 1: 111 OYSTER POINT BOULEVARD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: FIVE PRIME THERAPEUTICS INC DATE OF NAME CHANGE: 20020613 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-12-11 0 0001175505 FIVE PRIME THERAPEUTICS, INC. FPRX 0001229447 Smith David V 111 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080 0 1 0 0 Executive Vice President & CFO Common Stock 2020-12-11 4 M 0 22000 0.00 A 89561 D Common Stock 2020-12-11 4 F 0 11504 16.14 D 78057 D Performance-Based Restricted Common Stock 2020-12-11 4 M 0 22000 0.00 D Common Stock 22000 0 D Represents shares of performance-based restricted common stock granted to the reporting person on June 24, 2019. These shares vested on the date that the 30-calendar-day volume-weighted average closing price of a share of common stock of Five Prime Therapeutics, Inc. (the "Company") was greater than or equal to $19.43. The shares subject to this grant vest upon achievement of certain performance conditions, as further described in the other footnotes to this report. Represents 50% of the shares subject to this award, which shares vested on the date that the 30-calendar-day volume-weighted average closing price of a share of common stock of the Company was greater than or equal to $19.43. 50% of the shares subject to this award vested on the date that the 30-calendar-day volume-weighted average closing price of a share of common stock of the Company was greater than or equal to $12.95, and the remaining 50% of the shares subject to this award vested on the date that the 30-calendar-day volume-weighted average closing price of a share of common stock of the Company was greater than or equal to $19.43. /s/ Francis Sarena, Attorney-in-fact 2020-12-15